The presentation of positive trial results typically has a favorable impact on a pharmaceutical company's stock price, as it suggests potential for successful commercialization and revenue growth. Given the chronic nature of SCD and TDT, a drug that shows consistent and durable responses is likely to be well-received by both the medical community and the market, potentially leading to increased sales and market share for Vertex Pharmaceuticals.